210 related articles for article (PubMed ID: 36325350)
1. Identification of the immunosuppressive effect of γδ T cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia.
Liang S; Dong T; Yue K; Gao H; Wu N; Liu R; Chang Y; Hao L; Hu L; Zhao T; Jiang Q; Huang XJ; Liu J
Front Immunol; 2022; 13():1009709. PubMed ID: 36325350
[TBL] [Abstract][Full Text] [Related]
2. STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2
Cheng C; Liang S; Yue K; Wu N; Li Z; Dong T; Dong X; Ling M; Jiang Q; Liu J; Huang XJ
Cancer Lett; 2024 Apr; 587():216730. PubMed ID: 38360140
[TBL] [Abstract][Full Text] [Related]
3. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies.
Rao A; Agrawal A; Borthakur G; Battula VL; Maiti A
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417915
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
5. High
Kong X; Zheng J; Liu X; Wang W; Jiang X; Chen J; Lai J; Jin Z; Wu X
Front Immunol; 2022; 13():823352. PubMed ID: 35222403
[TBL] [Abstract][Full Text] [Related]
6. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells.
Le Floch AC; Rouvière MS; Salem N; Ben Amara A; Orlanducci F; Vey N; Gorvel L; Chretien AS; Olive D
Cells; 2023 Jun; 12(13):. PubMed ID: 37443727
[TBL] [Abstract][Full Text] [Related]
9. Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia.
Jin Z; Luo Q; Lu S; Wang X; He Z; Lai J; Chen S; Yang L; Wu X; Li Y
J Hematol Oncol; 2016 Nov; 9(1):126. PubMed ID: 27863523
[TBL] [Abstract][Full Text] [Related]
10. CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vδ2
Dong T; Wu N; Gao H; Liang S; Dong X; Zhao T; Jiang Q; Liu J
Ann Hematol; 2022 Oct; 101(10):2195-2208. PubMed ID: 35920929
[TBL] [Abstract][Full Text] [Related]
11. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
12. Higher TIGIT+ γδ T
Hou Q; Wang P; Kong X; Chen J; Yao C; Luo X; Li Y; Jin Z; Wu X
Front Immunol; 2024; 15():1321126. PubMed ID: 38711501
[TBL] [Abstract][Full Text] [Related]
13. Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S; Chevalier MF; Benmerzoug S; Cesson V; Schneider AK; Rodrigues-Dias SC; Dartiguenave F; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002184
[No Abstract] [Full Text] [Related]
14. Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2
He W; Hu Y; Chen D; Li Y; Ye D; Zhao Q; Lin L; Shi X; Lu L; Yin Z; He X; Gao Y; Wu Y
Clin Transl Med; 2022 Apr; 12(4):e800. PubMed ID: 35390227
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the gammadelta T cell response to acute leukemia.
Meeh PF; King M; O'Brien RL; Muga S; Buckhalts P; Neuberg R; Lamb LS
Cancer Immunol Immunother; 2006 Sep; 55(9):1072-80. PubMed ID: 16328383
[TBL] [Abstract][Full Text] [Related]
16. Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.
Branella GM; Lee JY; Okalova J; Parwani KK; Alexander JS; Arthuzo RF; Fedanov A; Yu B; McCarty D; Brown HC; Chandrakasan S; Petrich BG; Doering CB; Spencer HT
Front Immunol; 2023; 14():1294555. PubMed ID: 38022523
[TBL] [Abstract][Full Text] [Related]
17. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.
Wang H; Chen H; Liu S; Zhang J; Lu H; Somasundaram R; Choi R; Zhang G; Ou L; Scholler J; Tian S; Dong L; Yeye G; Huang L; Connelly T; Li L; Huang A; Mitchell TC; Fan Y; June CH; Mills GB; Guo W; Herlyn M; Xu X
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34937742
[TBL] [Abstract][Full Text] [Related]
18. Prospects for immunotherapy of acute myeloid leukemia using γδ T cells.
Halim L; Parente-Pereira AC; Maher J
Immunotherapy; 2017 Jan; 9(2):111-114. PubMed ID: 28128710
[No Abstract] [Full Text] [Related]
19. Dendritic Cells Are Critical for the Activation and Expansion of Vδ2
Wang X; Liu J; Gao H; Mo XD; Han T; Xu LP; Zhang XH; Huang XJ
Front Immunol; 2018; 9():2528. PubMed ID: 30443256
[TBL] [Abstract][Full Text] [Related]
20. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
